Adial Pharmaceuticals, Inc. (ADIL) Stock

Adial Pharmaceuticals, Inc. (ADIL) is a Healthcare stock trading at $6.26 (as of 2026-08-21), with a market capitalization of $13.42M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for addiction and related disorders. Its lead candidate, AD04, is a selective serotonin-3 antagonist in Phase III for alcohol use disorder, and the company also develops additional drug candidates for non-opioid pain reduction and other diseases.

Understand Adial Pharmaceuticals, Inc.: how it makes money

Adial Pharmaceuticals develops clinical-stage biopharmaceutical therapeutics for addiction and related disorders, led by AD04 (a selective serotonin-3 antagonist) in Phase III for alcohol use disorder, and it currently has no reported product revenue as it works toward future development and approval.

With AD04 in Phase III and no reported revenue, the profit model is structurally driven by clinical progress and the ability to fund ongoing development, not by existing product sales.

Business quality (Weak): Clinical-stage company with no reportable segments and no provided operating KPIs, so near-term investor focus is on Phase III progress and financing needs rather than unit metrics.

Bull case

  • AD04 is in Phase III for alcohol use disorder: The lead product, AD04, is a selective serotonin-3 antagonist being tested in Phase III for the treatment of alcohol use disorder.
  • Focused pipeline beyond alcohol use disorder: The company is also developing drug candidates for non-opioid pain reduction and other diseases and disorders.

Bear case

  • No reported revenue: For the period ended 2026-03-31, revenue is reported as 0.0B, indicating the business has not yet reached product sales in this dataset.
  • Large operating losses: Operating margin is reported as -4253.1 for the period ended 2026-03-31, reflecting ongoing operating expense relative to revenue.
  • Clinical and regulatory execution risk: Because the lead asset is in Phase III and the company is focused on development, unfavorable trial or regulatory outcomes could limit the path to commercialization.
Valuation — source: SEC EDGAR (first-party)
Price$6.26
Market Cap$13.42M
Price / Sales67.10
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$149567.00
Net Margin-5333.5%
Return on Equity150.6%
Current Ratio5.63
Revenue Growth (YoY)-16.3%
EPS Growth (YoY)338.6%
Financial Health — source: SEC EDGAR
Altman Z-Score-18.01 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderARMISTICE CAPITAL, LLC ($561977.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOCary John Claiborne
Employees5
CountryUS
IPO Date2018-07-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Imunon, Inc. (IMNN)
  • Traws Pharma, Inc. (TRAW)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • Soligenix, Inc. (SNGX)
  • GeoVax Labs, Inc. (GOVX)
  • Exicure, Inc. (XCUR)
  • Azitra, Inc. (AZTR)
  • Kairos Pharma, Ltd. (KAPA)
ADIL earnings history · ADIL institutional & insider holders · ADIL KPIs & operating metrics · ADIL financials · ADIL investor presentations & press releases · ADIL SEC filings · ADIL peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.